The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

Clinical Infectious Diseases

Volumn 25, Issue 5, 1997, Pages 1213-1221

  Alangaden, George J ^a   Lerner, Stephen A ^b  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PEFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; COMBINATION CHEMOTHERAPY; CRYSTALLURIA; DRUG CHOICE; DRUG EFFICACY; FACE EDEMA; FLU LIKE SYNDROME; HUMAN; LEPROSY; MYCOBACTERIOSIS; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; TREMOR; TUBERCULOSIS;

EID: 0030785442     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516116     Document Type: Review

References (18)

1. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989;33:1-5.
2. Garcia-Rodriguez JA, Garcia ACG. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808.
3. Gelber RH, Iranmanesh A, Murray L, Siu P, Tsang M. Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob Agents Chemother 1992;36:2544-7.
4. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
5. Cambau E, Sougakoff W, Desson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994;170:479-83.
6. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995;39:1700-3.
7. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994;11:242-51.
8. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985;28:716-21.
9. Von Rosenstiel N, Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use (published erratum appears in Drugs 1994;48:326). Drugs 1994;47:872-901.
10. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993;32:897-902.
11. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-6.
12. Yew WW, Kwan SY, Ma WK, Khin MA, Chau PY. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990;26:227-36.
13. Kahana LM, Spino M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP 1991;25:919-24.
14. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992;102:1815-8.
15. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992;73:59-67.
16. Mohanty KC, Dhamgaye TM. Controlled trial of Ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104:1194-8.
17. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993;148:1547-51.
18. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22:827-33.